A systematic review of salivary biomarkers in Parkinson's disease

Maria Ilenia De Bartolo; Daniele Belvisi; Romina Mancinelli; Matteo Costanzo; Claudia Caturano; Giorgio Leodori; Alfredo Berardelli; Giovanni Fabbrini; Giorgio Vivacqua

doi:10.4103/NRR.NRR-D-23-01677

A systematic review of salivary biomarkers in Parkinson's disease

Neural Regen Res. 2024 Dec 1;19(12):2613-2625. doi: 10.4103/NRR.NRR-D-23-01677. Epub 2024 Mar 1.

Authors

Maria Ilenia De Bartolo¹, Daniele Belvisi^{1

2}, Romina Mancinelli³, Matteo Costanzo¹, Claudia Caturano⁴, Giorgio Leodori^{1

2}, Alfredo Berardelli^{1

2}, Giovanni Fabbrini^{1

2}, Giorgio Vivacqua⁴

Affiliations

¹ IRCCS Neuromed, Pozzilli, Italy.
² Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
³ Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
⁴ Department of Experimental Morphology and Microscopy -Integrated Research Center (PRAAB) -Campus Biomedico University of Rome, Rome, Italy.

PMID: 38595280
DOI: 10.4103/NRR.NRR-D-23-01677

Abstract

The search for reliable and easily accessible biomarkers in Parkinson's disease is receiving a growing emphasis, to detect neurodegeneration from the prodromal phase and to enforce disease-modifying therapies. Despite the need for non-invasively accessible biomarkers, the majority of the studies have pointed to cerebrospinal fluid or peripheral biopsies biomarkers, which require invasive collection procedures. Saliva represents an easily accessible biofluid and an incredibly wide source of molecular biomarkers. In the present study, after presenting the morphological and biological bases for looking at saliva in the search of biomarkers for Parkinson's disease, we systematically reviewed the results achieved so far in the saliva of different cohorts of Parkinson's disease patients. A comprehensive literature search on PubMed and SCOPUS led to the discovery of 289 articles. After screening and exclusion, 34 relevant articles were derived for systematic review. Alpha-synuclein, the histopathological hallmark of Parkinson's disease, has been the most investigated Parkinson's disease biomarker in saliva, with oligomeric alpha-synuclein consistently found increased in Parkinson's disease patients in comparison to healthy controls, while conflicting results have been reported regarding the levels of total alpha-synuclein and phosphorylated alpha-synuclein, and few studies described an increased oligomeric alpha-synuclein/total alpha-synuclein ratio in Parkinson's disease. Beyond alpha-synuclein, other biomarkers targeting different molecular pathways have been explored in the saliva of Parkinson's disease patients: total tau, phosphorylated tau, amyloid-β1-42 (pathological protein aggregation biomarkers); DJ-1, heme-oxygenase-1, metabolites (altered energy homeostasis biomarkers); MAPLC-3beta (aberrant proteostasis biomarker); cortisol, tumor necrosis factor-alpha (inflammation biomarkers); DNA methylation, miRNA (DNA/RNA defects biomarkers); acetylcholinesterase activity (synaptic and neuronal network dysfunction biomarkers); Raman spectra, proteome, and caffeine. Despite a few studies investigating biomarkers targeting molecular pathways different from alpha-synuclein in Parkinson's disease, these results should be replicated and observed in studies on larger cohorts, considering the potential role of these biomarkers in determining the molecular variance among Parkinson's disease subtypes. Although the need for standardization in sample collection and processing, salivary-based biomarkers studies have reported encouraging results, calling for large-scale longitudinal studies and multicentric assessments, given the great molecular potentials and the non-invasive accessibility of saliva.